RUNA digital repository

    • Español
    • Galego
    • English
  • English 
    • Español
    • Galego
    • English
  • Login
RUNABibliosaúdeXunta de galicia. Consellería de sanidadeServicio Galego de saúde
  • REPOSITORY
  • ABOUT US
    • About RUNA
    • Normative
    • Sergas Policy
  • HELP
    • Help
    • FAQ
  •   RUNA Home
  • Scientific publication
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution

Lauper, K.; Mongin, D.; Alpizar-Rodriguez, D.; Codreanu, C.; Iannone, F.; Kristianslund, E. K.; Kvien, T. K.; Pavelka, K.; Pombo Suárez, Manuel; Santos, M. J.; Gabay, C.; Finckh, A.; Courvoisier, D. S.
Thumbnail
Statistics
Statistics
View Usage Statistics
Identifiers
Identifiers
URI: http://hdl.handle.net/20.500.11940/15488
PMID: 31209481
DOI: 10.1093/rheumatology/kez221
ISSN: 1462-0324
Full record
Services
Services
RISMendeleyLinksolver
Files view or download
Files view or download
Rheumatology (Oxford). 2019 Dec 1;58(12):2221-2229. doi: 10.1093/rheumatology/kez221. (519.6Kb)
Versión del editor (30.87Kb)
Date issued
2019
Journal title
RHEUMATOLOGY
Type of content
Artigo
Abstract
OBJECTIVE: To examine the association of the evolution in physician-reported and patient-reported outcomes with decision to stop biological DMARDs (bDMARDs) in RA. The contribution of baseline characteristics is well established, but little is known about how the disease evolution influences the decision to discontinue therapy. METHODS: RA patients who initiated a bDMARD treatment from 2009 and with information on date of visit were pooled from seven European RA registers. Each outcome was divided into baseline assessments (capturing the inter-individual differences at drug initiation) and changes from baseline at subsequent visits (capturing the individual evolution). Cox regression models were used to examine their association with drug discontinuation, adjusting for baseline patient and co-therapy characteristics and stratifying by register and calendar year of drug initiation. RESULTS: A total of 25 077 patients initiated a bDMARDs (18 507 a TNF-inhibitor, 3863 tocilizumab and 2707 abatacept) contributing an amount of 46 456.8 patient-years. Overall, drug discontinuation was most strongly associated with a poor evolution of the DAS28, with a hazard ratio of 1.34 (95% CI 1.29, 1.40), followed by its baseline value. A change of Physician Global Assessment was the next strongest predictor of discontinuation, then the Patient Global Assessment. CONCLUSIONS: The decision to discontinue treatments appears to be mostly influenced by DAS28 and particularly its evolution over time, followed by Physician Global Assessment evolution, suggesting that the decision to stop bDMARDs relies more on the physician's than on the patient's global assessment.

Browse

All of RUNACollectionsCentersAuthorsTitlesDeCSMeSHCIETypes of contentThis CollectionCentersAuthorsTitlesDeCSMeSHCIETypes of content

Statistics

View Usage Statistics

OF INTEREST

About Open AccessCopyright
TwitterRSS
Xunta de Galicia
© Xunta de Galicia. Información mantida e publicada na internet pola Consellería de Sanidade o Servizo Galego de Saúde
Legal warning | RSS
Galicia